Updating results

477 results

Sort: Relevance | Date

Managing medicines for adults receiving social care in the community (NG67)

This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.

NICE guideline Published March 2017

Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)

This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.

NICE guideline Published August 2015

Developing and updating local formularies (MPG1)

This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.

Medicines practice guideline Published March 2014 Last updated October 2015

Patient group directions (MPG2)

This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

Medicines practice guideline Published August 2013 Last updated March 2017

Controlled drugs: safe use and management (NG46)

This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.

NICE guideline Published April 2016

Transition between inpatient hospital settings and community or care home settings for adults with social care needs (NG27)

This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.

NICE guideline Published December 2015

Managing medicines in care homes (SC1)

This guideline covers good practice for managing medicines in care homes. It aims to promote the safe and effective use of medicines in care homes by advising on processes for prescribing, handling and administering medicines. It also recommends how care and services relating to medicines should be provided to people living in care homes.

Social care guideline Published March 2014

Transition from children's to adults' services for young people using health or social care services (NG43)

This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.

NICE guideline Published February 2016

People's experience in adult social care services: improving the experience of care and support for people using adult social care services (NG86)

This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.

NICE guideline Published February 2018

Transition between inpatient mental health settings and community or care home settings (NG53)

This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

NICE guideline Published August 2016

Home care: delivering personal care and practical support to older people living in their own homes (NG21)

This guideline covers the planning and delivery of person-centred care for older people living in their own homes (known as home care or domiciliary care). It aims to promote older people's independence and to ensure safe and consistently high quality home care services.

NICE guideline Published September 2015

Learning disabilities and behaviour that challenges: service design and delivery (NG93)

This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.

NICE guideline Published March 2018

Care and support of people growing older with learning disabilities (NG96)

This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.

NICE guideline Published April 2018

Older people with social care needs and multiple long-term conditions (NG22)

This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.

NICE guideline Published November 2015

Decision-making and mental capacity (NG108)

This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

NICE guideline Published October 2018

Child abuse and neglect (NG76)

This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.

NICE guideline Published October 2017

Intermediate care including reablement (NG74)

This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.

NICE guideline Published September 2017

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Evidence-based recommendations on rucaparib (Rubraca) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to

Technology appraisal guidance Published November 2019

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults

Technology appraisal guidance Published November 2019

Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)

NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence

Technology appraisal guidance Published December 2018

Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)

NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published December 2018

Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Technology appraisal guidance Published March 2019

Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..

Technology appraisal guidance Published November 2014

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance Published October 2012

Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)

NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy

Technology appraisal guidance Published May 2017

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer

Technology appraisal guidance Published August 2019

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment (with trastuzumab and chemotherapy) of HER2-positive early stage breast cancer

Technology appraisal guidance Published March 2019

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults

Technology appraisal guidance Published June 2018

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

Evidence-based recommendations on ceritinib (Zykadia) for advanced anaplastic lymphoma kinase positive non-small-cell lung cancer...

Technology appraisal guidance Published June 2016

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

Technology appraisal guidance Published April 2013

Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)

NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...

Technology appraisal guidance Published March 2013

Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)

Evidence-based recommendations on pixantrone (Pixuvri) for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma

Technology appraisal guidance Published February 2014

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Technology appraisal guidance Published October 2019

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma

Technology appraisal guidance Published March 2009

Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)

Evidence-based recommendations on endovascular stent–grafts for the treatment of abdominal aortic aneurysms

Technology appraisal guidance Published February 2009

Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

Evidence-based recommendations on onhaled corticosteroids for treating chronic asthma in adults and children aged 12 years and over

Technology appraisal guidance Published March 2008

Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer

Technology appraisal guidance Published January 2007 Last updated January 2012

Stapled haemorrhoidopexy for the treatment of haemorrhoids (TA128)

Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids

Technology appraisal guidance Published September 2007

Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block

Technology appraisal guidance Published November 2014

Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

Evidence-based recommendations on human growth hormone (somatropin) for treating growth failure in children

Technology appraisal guidance Published May 2010

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating Crohn's disease in adults

Technology appraisal guidance Published May 2010

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma

Technology appraisal guidance Published August 2009

Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease (TA20)

Evidence-based recommendations on the use of Riluzole (Rilutek) for treating motor neurone disease (MND)

Technology appraisal guidance Published January 2001

Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)

Technology appraisal guidance Published November 2010

Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)

NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence

Technology appraisal guidance Published October 2010

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)

Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C

Technology appraisal guidance Published September 2010

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis

Technology appraisal guidance Published August 2010

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor

Technology appraisal guidance Published August 2010